2020 Sedation Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Sedation pipeline report presents a comprehensive overview of the research and development of Sedation drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in pre-clinical phase, one drug in Phase 1, one drug in Phase 2 and two drugs in Phase 3
As of February 2020, the Sedation pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Sedation treatment. Diverse types of targeted therapies are being explored through clinical trials including GABA A receptor agonists; NMDA receptor antagonists; hydroxytryptamine receptors antagonist .
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Sedation drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Sedation pipeline drugs profiled in the report include- alphaxalone, Remimazolam tosylate (HR-7056), EL-001, MELT-100 (ketamine+midazolam), remimazolam, SERx-480, HSK3486
As of February 2020, the Sedation pipeline remains robust with 7 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Sedation treatment. Diverse types of targeted therapies are being explored through clinical trials including GABA A receptor agonists; NMDA receptor antagonists; hydroxytryptamine receptors antagonist .
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Sedation drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Sedation development
- Sedation pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Sedation pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Sedation pipeline candidates included
- Business overview and snapshot of all companies involved in Sedation pipeline are included
- Latest market and pipeline developments are provided in the report
Sedation pipeline drugs profiled in the report include- alphaxalone, Remimazolam tosylate (HR-7056), EL-001, MELT-100 (ketamine+midazolam), remimazolam, SERx-480, HSK3486
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Sedation Condition
2.3 Sedation Pipeline Snapshot, 2020
2.4 Companies investing in Sedation pipeline therapeutics
2.5 Phase wise Sedation Pipeline Candidates
2.6 Most Researched Mechanism of Action of Sedation Pipeline Products
2.7 Route of Administration of Sedation Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Drawbridge Pharmaceuticals Pty Ltd Overview, Contacts and ASD Pipeline Drugs
3.2 Jiangsu Hengrui Medicine Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Jiangsu Nhwa Pharmaceutical Corp Ltd Overview, Contacts and ASD Pipeline Drugs
3.4 Melt Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Paion AG Overview, Contacts and ASD Pipeline Drugs
3.6 Seropeutics LLC Overview, Contacts and ASD Pipeline Drugs
3.7 Sichuan Haisco Pharmaceutical Group Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 alphaxalone Drug Details
4.1.1 alphaxalone Current Status
4.1.2 alphaxalone Drug Overview
4.1.3 alphaxalone Mechanism of Action
4.1.4 alphaxalone Licensing/Collaboration Companies
4.1.5 alphaxalone Clinical Trials
4.2 Remimazolam tosylate (HR-7056) Drug Details
4.2.1 Remimazolam tosylate (HR-7056) Current Status
4.2.2 Remimazolam tosylate (HR-7056) Drug Overview
4.2.3 Remimazolam tosylate (HR-7056) Mechanism of Action
4.2.4 Remimazolam tosylate (HR-7056) Licensing/Collaboration Companies
4.2.5 Remimazolam tosylate (HR-7056) Clinical Trials
4.3 EL-001 Drug Details
4.3.1 EL-001 Current Status
4.3.2 EL-001 Drug Overview
4.3.3 EL-001 Mechanism of Action
4.3.4 EL-001 Licensing/Collaboration Companies
4.3.5 EL-001 Clinical Trials
4.4 MELT-100 (ketamine+midazolam) Drug Details
4.4.1 MELT-100 (ketamine+midazolam) Current Status
4.4.2 MELT-100 (ketamine+midazolam) Drug Overview
4.4.3 MELT-100 (ketamine+midazolam) Mechanism of Action
4.4.4 MELT-100 (ketamine+midazolam) Licensing/Collaboration Companies
4.4.5 MELT-100 (ketamine+midazolam) Clinical Trials
4.5 remimazolam Drug Details
4.5.1 remimazolam Current Status
4.5.2 remimazolam Drug Overview
4.5.3 remimazolam Mechanism of Action
4.5.4 remimazolam Licensing/Collaboration Companies
4.5.5 remimazolam Clinical Trials
4.6 SERx-480 Drug Details
4.6.1 SERx-480 Current Status
4.6.2 SERx-480 Drug Overview
4.6.3 SERx-480 Mechanism of Action
4.6.4 SERx-480 Licensing/Collaboration Companies
4.6.5 SERx-480 Clinical Trials
4.7 HSK3486 Drug Details
4.7.1 HSK3486 Current Status
4.7.2 HSK3486 Drug Overview
4.7.3 HSK3486 Mechanism of Action
4.7.4 HSK3486 Licensing/Collaboration Companies
4.7.5 HSK3486 Clinical Trials
5. LATEST SEDATION PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Sedation Condition
2.3 Sedation Pipeline Snapshot, 2020
2.4 Companies investing in Sedation pipeline therapeutics
2.5 Phase wise Sedation Pipeline Candidates
2.6 Most Researched Mechanism of Action of Sedation Pipeline Products
2.7 Route of Administration of Sedation Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Drawbridge Pharmaceuticals Pty Ltd Overview, Contacts and ASD Pipeline Drugs
3.2 Jiangsu Hengrui Medicine Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Jiangsu Nhwa Pharmaceutical Corp Ltd Overview, Contacts and ASD Pipeline Drugs
3.4 Melt Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Paion AG Overview, Contacts and ASD Pipeline Drugs
3.6 Seropeutics LLC Overview, Contacts and ASD Pipeline Drugs
3.7 Sichuan Haisco Pharmaceutical Group Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 alphaxalone Drug Details
4.1.1 alphaxalone Current Status
4.1.2 alphaxalone Drug Overview
4.1.3 alphaxalone Mechanism of Action
4.1.4 alphaxalone Licensing/Collaboration Companies
4.1.5 alphaxalone Clinical Trials
4.2 Remimazolam tosylate (HR-7056) Drug Details
4.2.1 Remimazolam tosylate (HR-7056) Current Status
4.2.2 Remimazolam tosylate (HR-7056) Drug Overview
4.2.3 Remimazolam tosylate (HR-7056) Mechanism of Action
4.2.4 Remimazolam tosylate (HR-7056) Licensing/Collaboration Companies
4.2.5 Remimazolam tosylate (HR-7056) Clinical Trials
4.3 EL-001 Drug Details
4.3.1 EL-001 Current Status
4.3.2 EL-001 Drug Overview
4.3.3 EL-001 Mechanism of Action
4.3.4 EL-001 Licensing/Collaboration Companies
4.3.5 EL-001 Clinical Trials
4.4 MELT-100 (ketamine+midazolam) Drug Details
4.4.1 MELT-100 (ketamine+midazolam) Current Status
4.4.2 MELT-100 (ketamine+midazolam) Drug Overview
4.4.3 MELT-100 (ketamine+midazolam) Mechanism of Action
4.4.4 MELT-100 (ketamine+midazolam) Licensing/Collaboration Companies
4.4.5 MELT-100 (ketamine+midazolam) Clinical Trials
4.5 remimazolam Drug Details
4.5.1 remimazolam Current Status
4.5.2 remimazolam Drug Overview
4.5.3 remimazolam Mechanism of Action
4.5.4 remimazolam Licensing/Collaboration Companies
4.5.5 remimazolam Clinical Trials
4.6 SERx-480 Drug Details
4.6.1 SERx-480 Current Status
4.6.2 SERx-480 Drug Overview
4.6.3 SERx-480 Mechanism of Action
4.6.4 SERx-480 Licensing/Collaboration Companies
4.6.5 SERx-480 Clinical Trials
4.7 HSK3486 Drug Details
4.7.1 HSK3486 Current Status
4.7.2 HSK3486 Drug Overview
4.7.3 HSK3486 Mechanism of Action
4.7.4 HSK3486 Licensing/Collaboration Companies
4.7.5 HSK3486 Clinical Trials
5. LATEST SEDATION PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
